- Wen Yongjun, from Xichong, Sichuan Province, graduated from Lanzhou University with a master of Science Degree in July 1991.
- China began to have the ability to prepare synthetic multi skin drugs on a large scale. At present, China’s multi skin drug industry is still in its infancy and growth stage, with great potential for development.
- Chengdu shengnuo biopharmaceutical Co., Ltd. also has a number of products under development, of which three have submitted applications for listing.
Wen Yongjun, from Xichong, Sichuan Province, graduated from Lanzhou University with a master of Science Degree in July 1991.
He is currently the chairman and general manager of Chengdu suno Biotechnology Co., Ltd., and a member of Expert Committee of China biochemical pharmaceutical industry association. He has successively served as director of Hainan Zhonghe Group Pharmaceutical Research Institute and director of Chengdu Di’ao Pharmaceutical Group Pharmaceutical Research Institute.
From 1991 to 1997, he presided over the development of the first SFDA approved multi skin drug thymus Wufu; from 1997 to 2003, he presided over the development of the second SFDA approved multi skin drug thymosin; from 2003 to 2007, he presided over the development of China’s third multi skin drug, somatostatin; in 2008, it won the 10th prize “Outstanding contribution award of multi skin application” was awarded by China International multi skin Conference;
outstanding contribution award of multi skin application was awarded by the 12th China International multi skin conference in 2012; and “outstanding talent award” was awarded by the 2nd National multi skin drug research and development and large-scale production frontier technology exchange meeting in 2016.
On August 15-17, 2019, chairman Wen Yongjun made a report on the current situation of large-scale production of multi skin drugs in China at the first China multi skin industry forum and the establishment meeting of multi skin branch of China biochemical pharmaceutical industry association. According to the report, the development of China’s multi skin industry began in the 1990s In the early s of the s, multinational enterprises such as Novartis Pharmaceutical Co., Ltd., syrano Co., Ltd.
and saisheng Pharmaceutical Co., Ltd. applied to China for registration of a number of synthetic multi skin drugs, such as Sandostatin (octrifen for injection), sitamin (somatostatin for injection), minocycline (frog calcitonin injection), ridaxine (thymus for injection), etc Things began to enter China and achieved market success.
At the end of the 1990s, domestic enterprises began to pay attention to the chemical synthesis of multi skin drugs, and began to invest financial resources for R & D and registration. However, limited by technology and hardware equipment, until the end of the last century, only thymus pentadermis was approved by s “OA”. The supply of equipment and raw and auxiliary materials such as multi skin synthetic instrument, preparative grade chromatography, protective aminophthalein, resin and other equipment and raw and auxiliary materials are all dependent on imports.
Due to the relative shortage of domestic supporting facilities, it is difficult for domestic enterprises to produce chemical synthetic multi skin drugs on a large scale. In the 21st century, with more and more pharmaceutical enterprises’ attention and large amount of investment, synthetic multi skin drugs have been vigorously developed in China, including the application of various preparation technologies, the supply of key raw materials, and the gradual maturity of relevant supporting equipment.
China began to have the ability to prepare synthetic multi skin drugs on a large scale. At present, China’s multi skin drug industry is still in its infancy and growth stage, with great potential for development.
Although the “global new” polyskin molecule is in its infancy in China, innovative drugs are catching up with the “east wind” of deepening the reform of drug review and approval system. Products with clear clinical efficacy that have not been listed at home and abroad will be speeded up.
Chengdu Shengnuo Biotechnology Co., Ltd. was established in 2001, with more than 500 employees and an area of 275 mu. Chengdu shengnuo biopharmaceutical Co., Ltd., a subsidiary, has passed the official GMP of China, the United States, South Korea and Mexico successively Multi skin preparation production line includes solid preparations and injections, of which the injection production workshop covers freeze-dried powder injection, penicillin bottle injection, pre filling injection and cartridge injection production lines;
in addition to its own API and multi skin drug preparation projects, the company also provides professional multi skin drug research and development services to undertake domestic and foreign multi skin drug Objective to innovate cro / C (o) Mo business of multi skin project. The company has the most perfect multi skin drug research platform in China, including independent raw material test / pilot production workshop, independent preparation small / pilot production workshop and corresponding independent research team.
The company has successfully realized the industrialization transformation of many first class multi skin new drugs for Chengdu Dior, Zhejiang Haizheng, Harbin Pharmaceutical Group, Hainan Zhonghe and frontier Biology (Nanjing).
Chengdu shengnuo biopharmaceutical Co., Ltd. also has a number of products under development, of which three have submitted applications for listing.
The listing application of “blockbuster” lilalufu injection was accepted by CDE on October 29, 2018. Liragufu is a glucagon like skin-1 (GLP-1) analogue, which can activate human GLP-1 receptor, promote insulin secretion, and reduce body weight, cardiovascular risk and cardiovascular death risk.
Liragufu injection has been approved in China for the control of blood glucose in adult patients with type 2 diabetes. In July 2017, the price was reduced by about 43% and entered the national medical insurance drug list. It is the only GLP-1 analogue in the current medical insurance list. Liragufu is the best-selling GLP-1 receptor agonist in the world. In 2018, the global sales volume reached 4.468 billion U.S.
dollars, and the sales of terminals in China’s public medical institutions were nearly 500 million yuan, with a year-on-year increase of nearly 50%. At present, the domestic market of liragufu is monopolized by Novo Nordisk, the original research manufacturer.
However, many enterprises have set up lilalufu generic drugs. Chengdu sannuo biopharmaceutical Co., Ltd. (lexima shares 9% of Chengdu suno Technology) has applied for listing according to the four categories of chemical drugs, which has been accepted in October, 2018. Moreover, the company is the raw material supplier of liragufu DMF in the United States, so it has a large cost advantage in mass production.
Chengdu Shengnuo Biotechnology Co., Ltd. has a technical and management team with senior professionals such as highly educated and senior engineers as the backbone. It has successively won the top innovation and Entrepreneurship of “national high tech enterprise”, “Sichuan enterprise technology center”, “member unit of Sichuan strategic emerging industry promotion association” and “thousand talents plan” of Sichuan high-level talents “Team” and other honorary titles.
The company pays attention to the combination of production, teaching and research, and has formed a close strategic partnership with Sichuan University, Lanzhou University, Jilin University, Academy of Military Sciences, organic Institute of Chinese Academy of Sciences, and Provincial Institute of drug control. It has established “Sichuan multi skin drug engineering technology research center” and “shengnuo biology Sichuan University industry university research joint laboratory”.
Chengdu shengnuo biopharmaceutical Co., Ltd. has participated in the national 11th five year plan major new drug creation project “key technology research on skin chemical modification and industrial scale preparation”.
The top project of “new anti heart failure drug nesilifu” funded by the national science and technology oriented zhongdiao and enterprise technology innovation fund has entered the clinical research stage, 2010 In 2004, it obtained the special fund support from Sichuan Provincial Economic Committee for emerging industries, and carried out the research on the transformation of multi skin medicine industrialization achievements.
It has more than 50 key technologies for large-scale production of multi skin drugs and products that have been listed at home and abroad, and the single batch output can reach kg level; it has international leading technologies such as sulfur ring skin large-scale production technology, carbon ring skin large-scale production technology, complex skin technology, multi skin rapid synthesis technology, and has applied for more than 40 invention patents (including PCT patents), with 20 It has become the key to the domestic patent industry.
For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide
Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……
How many companies are there in peptide api manufacturer in china? The peptide api market is very promising, and the world is encouraging the development of peptide business. There is a peptide api list on the website Biofda.com, which contains various specifications of peptide APIs for customers to choose from. Shengnuo Technology is a peptide api manufacturer located in Chengdu, a city in southwest China. Not only peptide APIs, but also carnosine custom suppliers and cosmetic peptide suppliers
are many peptide apis manufacture in China, but they are all small-scale companies. The China peptide company such as Sinotech is a leading company in China and has a very high position.
As a Chinese peptide company, Sinotech has been working silently, hoping to become a top peptide company in the world. There are many countries producing peptides in the world, such as bulk drug substance in India, gmp custom peptide in uk, and peptide production in usa. So what is polypeptide? What kind of peptide synthesis supplier should you choose? Follow our website: www.biofda.com, here will tell you the answer.